The role of neoadjuvant therapy in multimodality treatment of locally advanced esophageal squamous cell carcinoma: perspective from the NEOCRTEC5010 trial
10.3760/cma.j.cn112139-20210109-00021
- VernacularTitle:从NEOCRTEC5010研究看新辅助治疗在局部进展期食管鳞状细胞癌多学科综合治疗中的地位
- Author:
Xufeng GUO
1
;
Wentao FANG
Author Information
1. 上海市胸科医院 上海交通大学附属胸科医院胸外科 200030
- Keywords:
Esophageal neoplasms;
Thoracic surgical procedures;
Neoadjuvant therapy;
Lymph node dissection;
Immunotherapy
- From:
Chinese Journal of Surgery
2021;59(8):646-650
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of surgery alone for locally advanced esophageal cancer is poor, which requires the active participation of multimodality treatment. Neoadjuvant therapy, especially neoadjuvant chemoradiotherapy, could significantly lead to tumor downstage, bring higher radical resection rate and improve the prognosis. The NEOCRTEC5010 trial, a multicenter prospective randomized controlled trial on neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma has provided sufficient and valuable evidence for us, especially for some key questions after neoadjuvant chemoradiotherapy, such as perioperative complications, value of systemic lymphadenectomy, the post-operation recurrence pattern, pathological complete response, long-term prognosis and survival. In addition, the current development of tumor immunotherapy is so rapid that the role of immunotherapy in the first line treatment of advanced or relapsed/metastatic esophageal cancer has been confirmed. In the near future, neoadjuvant therapy based on immunnology-led combined with traditional chemoradiotherapy or chemotherapy is expected to become a new theraputic strategy to further improve the treatment efficacy of locally advanced esophageal squamous cell carcinoma. This paper focused on the classical research of neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma and the development of immunotherapy for esophageal cancer, aiming to improve the understanding of neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. This will help to carry out optimal clinical work and to design better clinical study.
